Heart Leaflet Technologies Valve Study (HLT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00710775|
Recruitment Status : Unknown
Verified May 2008 by Centro Cardiologico Monzino.
Recruitment status was: Recruiting
First Posted : July 4, 2008
Last Update Posted : October 12, 2009
The study will be conducted in patients who are undergoing surgical aortic valve replacement on cardiopulmonary bypass. Following surgical access of the native aortic valve and prior to removal of the valve, the native valve will be dilated using a standard valve dilation balloon. The Heart Leaflet Technologies(HLT- Heart Leaflet Technologies Inc.) aortic valve device will be released in the native valve and measurements will be taken of the device relative to the anatomic structures of the heart. Once completed, the implant is removed from the native valve and the surgical valve replacement procedure is completed.
The purpose of this study is to confirm that the dimensions of the HLT valve are appropriate for patients with aortic valve stenosis.
|Condition or disease||Intervention/treatment|
|Aortic Valve Stenosis Endovascular Aortic Valve Replacement||Procedure: surgical replacement of the aortic stenotic valve|
Aortic valve stenosis is a disease in which the leaflets of the aortic valve become scarred and calcified. This leads to a severe narrowing of the valve orifice, which causes chest pain, heart failure and eventually death. The condition is currently treated with open chest surgical valve replacement on cardiopulmonary bypass. Heart Leaflet Technologies has developed an aortic valve prosthesis that can be delivered to the stenotic aortic valve through a catheter inserted in the femoral artery.
The purpose of this study is to confirm that the dimensions of the HLT valve are appropriate for patients with aortic valve stenosis. There is no animal model of aortic valve stenosis. Heart Leaflet Technologies has performed extensive device geometry and deployment testing on fixed cadaveric hearts with calcified cusps and aortic stenosis. HLT has also performed a number of preclinical animal experiments to verify deliverability and device function in vivo.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||7 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Temporary Intra-operative Placement of HLT Percutaneous Aortic Valve|
|Study Start Date :||November 2007|
|Estimated Primary Completion Date :||December 2008|
|Estimated Study Completion Date :||December 2008|
Patients undergoing surgical aortic valve replacement on cardiopulmonary bypass.
Procedure: surgical replacement of the aortic stenotic valve
Prior to surgical removal of the aortic valve, the native valve will be dilated under direct vision of the surgeon using a standard valve dilation balloon. The HLT valve will be loaded into a short version of the delivery catheter system and the catheter will be passed across the native valve.Measurements will be taken of the device relative to the anatomic structures of the heart. Once complete, the implant is removed from the native valve and the surgical valve replacement procedure is completed.
Other Name: AVR (aortic valve replacement)
- geometrical evaluation of HLT pliability to patient's native aortic valve [ Time Frame: during surgery procedure ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00710775
|Contact: Paolo Biglioli, MD||+39/02/5800 ext email@example.com|
|Contact: Luca Dainese, MD||+39/02/5800 ext firstname.lastname@example.org|
|Centro Cardiologico Monzino- University of Milan, Italy||Recruiting|
|Milan, Italy, 20138|
|Contact: Paolo Biglioli, MD +39/02/5800 ext 2373 email@example.com|
|Contact: Luca Dainese, MD +39/02/5800 ext 2563 firstname.lastname@example.org|
|Sub-Investigator: Melissa Fusari, MD|
|Principal Investigator:||Paolo Biglioli, MD||Centro Cardiologico Monzino-University of Milan|